Ozempic vs Wegovy

If your social feed has made it look like Ozempic and Wegovy are two completely different drugs, here's the simpler truth: they share the same active ingredient (semaglutide) and the same manufacturer (Novo Nordisk). The brand name on the box changes based on what the FDA approved each version to treat.

Ozempic is approved for type 2 diabetes. Wegovy is approved for chronic weight management in adults with obesity or overweight plus a weight-related condition. Same molecule, different label, different maximum dose, different insurance pathway.

That distinction matters more than it sounds. It changes who can get a prescription covered, what the pharmacy charges, and how much weight loss you might reasonably expect.

At a glance

How they're alike

The active ingredient is identical. Both are semaglutide, a once-weekly subcutaneous injection that binds to the GLP-1 receptor. Both slow gastric emptying, blunt appetite signals from the gut and brain, and improve glucose handling. If you were blinded to the box, your body would respond to a 2.0 mg dose of Ozempic the same way it would respond to a 2.0 mg dose of Wegovy.

The injection device is similar too, just calibrated for different dose ranges. Both come in pre-filled pens, both go into the thigh, abdomen, or upper arm, and both follow a slow titration over several months to minimize gastrointestinal side effects.

Side effect profiles overlap almost perfectly. Nausea, constipation, diarrhea, fatigue, and the occasional sulfur burp are common companions for both. The intensity of those effects usually tracks dose, not brand.

How they're different

The biggest difference is the maximum dose. Ozempic tops out at 2.0 mg weekly. Wegovy goes to 2.4 mg, with a 7.2 mg high-dose option available for patients who need additional weight loss after at least four weeks at 2.4 mg. That extra headroom is part of why Wegovy is studied with weight loss as the primary endpoint while Ozempic is studied for glycemic control.

FDA approval drives prescribing and coverage. Insurance often pays for Ozempic when there is a type 2 diabetes diagnosis but rejects it for weight loss alone. Wegovy is the opposite: covered for obesity in some plans but not for diabetes. Off-label prescribing happens, but it complicates prior authorizations and out-of-pocket cost.

Trial outcomes differ for the same reason. The STEP 1 trial of semaglutide 2.4 mg (the Wegovy dose) showed roughly 14.9 percent mean body weight loss at 68 weeks. Ozempic trials such as SUSTAIN were designed around A1C reduction in people with type 2 diabetes, and weight loss is a secondary, smaller benefit. Dose, population, and study design all shape the headline number.

Which one is right for you?

The decision usually isn't a question of "which works better" but of "which one will my prescriber and my insurer agree to." If you have type 2 diabetes, Ozempic is typically the first conversation. If your goal is weight loss in the absence of diabetes, Wegovy is the on-label option and the one your provider can most easily justify to insurance.

Cost, supply, and side-effect tolerance matter too. Both drugs have had shortages, and both are expensive without coverage. Some patients tolerate the slower Wegovy titration well and stay at lower maintenance doses; others need the full 2.4 mg to see meaningful change. Bring honest data about your goals, your tolerance for nausea, and your budget into the conversation with your clinician.

Common questions

Keep exploring

Browse all GLP-1 guides or compare Wegovy and Zepbound head to head.